文献速递心律失常冠心病

房颤呈现模式与早期节律控制治疗的结果

Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

本研究为EAST-AFNET 4试验的预设分析,比较了首诊房颤、阵发性房颤和持续性房颤患者接受早期节律控制(ERC)与常规治疗的结局。结果显示ERC降低了所有三种房颤模式的主要复合终点,但首诊房颤患者住院和急性冠脉综合征风险较高,且ERC未改善其生活质量。

要点

  • ERC降低首诊、阵发和持续房颤患者的主要复合终点。
  • 首诊房颤患者急性冠脉综合征住院风险最高,尤其在接受ERC时。
  • ERC改善阵发和持续房颤的生活质量,但首诊房颤未见改善。

核心结论

  • ERC降低所有房颤模式的第一主要复合终点。
  • 首诊房颤患者住院和急性冠脉综合征风险高,尤其在ERC治疗下。

研究设计与样本

  • EAST-AFNET 4试验的预设分析,比较首诊房颤(n=1,048)、阵发性房颤(n=994)和持续性房颤(n=743)患者。
  • 平均随访5.1年,比较ERC与常规治疗的效果。

主要发现

  • 首诊房颤患者年龄71岁,女性48.0%;阵发性房颤70岁,女性50.0%;持续性房颤70岁,女性38.0%。
  • 急性冠脉综合征住院发生率比:首诊房颤1.50(95%CI 0.83-2.69;交互P=0.032),阵发性房颤0.64(95%CI 0.32-1.25),持续性房颤0.50(95%CI 0.25-1.00)。
  • 每年住院夜数发生率比:首诊房颤1.38(95%CI 1.12-1.70;交互P=0.004),阵发性房颤0.84(95%CI 0.67-1.03),持续性房颤1.02(95%CI 0.80-1.30)。
  • ERC改善阵发性和持续性房颤患者的EQ-5D生活质量评分,但首诊房颤患者未改善(P=0.019)。

临床怎么用

  • ERC可考虑用于所有房颤模式以降低主要复合终点。
  • 首诊房颤患者接受ERC时需警惕住院和急性冠脉综合征风险。
  • 阵发性和持续性房颤患者可从ERC中获得生活质量改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether atrial fibrillation (AF) pattern or timing of AF therapy modifies the effectiveness of early rhythm control (ERC) is not known. OBJECTIVES: This study sought to compare clinical characteristics and outcomes in patients presenting with different AF patterns on ERC vs usual care. METHODS: The effects of ERC were compared in first-diagnosed AF (FDAF), paroxysmal AF (paroxAF), and persistent AF (persAF) in this prespecified analysis of the EAST-AFNET 4 (Early treatment of atrial fibrillation for stroke prevention) trial. Associations between AF pattern and primary outcomes (first primary outcome: cardiovascular death, stroke, and hospitalization for heart failure and acute coronary syndrome; second primary outcome: nights spent in hospital per year) were compared over a mean follow-up of 5.1 years. Changes in health-related quality of life were assessed by the EQ-5D. RESULTS: FDAF patients (n = 1,048, enrolled 7 days after diagnosing AF) were slightly older (71 years of age, 48.0% female) than patients with paroxAF (n = 994, 70 years of age, 50.0% female) and persAF (n = 743, 70 years of age, 38.0% female). ERC reduced the primary outcome in all 3 AF patterns. Hospitalizations for acute coronary syndrome were highest in FDAF (incidence rate ratio [IRR]: 1.50; 95% CI: 0.83-2.69; P for interaction = 0.032) compared with paroxAF (IRR: 0.64; 95% CI: 0.32-1.25) and persAF (IRR: 0.50; 95% CI: 0.25-1.00). FDAF patients spent more nights in hospital (IRR: 1.38; 95% CI: 1.12-1.70; P for interaction = 0.004) than paroxAF (IRR: 0.84; 95% CI: 0.67-1.03), and persAF (IRR: 1.02; 95% CI: 0.80-1.30) patients. ERC improved health-related quality of life (EQ-5D score) in patients with paroxAF and persAF but not in patients with FDAF (P = 0.019). CONCLUSIONS: ERC reduces the first primary composite outcome in all AF patterns. Patients with FDAF are at high risk for hospitalization and acute coronary syndrome, particularly on ERC. (Early treatment of atrial fibrillation for stroke prevention trial; ISRCTN04708680; Early Treatment of Atrial Fibrillation for Stroke Prevention Trial [EAST]; NCT01288352; Early treatment of Atrial fibrillation for Stroke prevention Trial [EAST]; EudraCT2010-021258-20).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Goette, Borof, Breithardt, et al. Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy. J Am Coll Cardiol. 2022. PMID: 35863844. doi:10.1016/j.jacc.2022.04.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。